Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

Market Cap	12.91B +4.4%
Revenue (ttm)	2.98B +6.2%
Net Income	937.93M -10.8%
EPS	2.91 -10.7%
Shares Out	322.32M
PE Ratio	13.76
Forward PE	n/a
Dividend	1.76 (4.35%)
Ex-Dividend Date	n/a

Volume	2,287,428
Average Volume	2,842,052
Open	40.33
Previous Close	40.39
Day's Range	39.89 - 40.60
52-Week Range	34.93 - 57.98
Beta	0.38
RSI	37.97
Earnings Date	Apr 29, 2026

About SHA:600211

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-releas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 671
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600211

Financial Performance

In 2025, SHA:600211's revenue was 2.98 billion, an increase of 6.23% compared to the previous year's 2.81 billion. Earnings were 937.93 million, a decrease of -10.78%.